Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801


Por: Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM and Márquez-Rodas, I

Publicada: 1 may 2026 Ahead of Print: 1 nov 2025
Resumen:
PurposeAnti-PD-1-based immunotherapy and targeted therapies (TT) are the current standard of care for patients with advanced melanoma. However, some patients die in less than a year from diagnosis and others become long-survivors. An accurate description of systemic treatments and patients' characteristics of long-term survivors are needed to guide treatment decisions in clinical practice.MethodsGEM-1801 is a multi-cohort prospective study from the Spanish Multidisciplinary Melanoma Group that includes patients with resectable stage III or unresectable stage III/IV melanoma. Patients surviving at least 5 years and patients surviving less than 1 year since diagnosis were selected. Baseline characteristics and first and second-line systemic treatments are described and compared between groups.ResultsFrom Aug 2018 to Dec 2023, 60 patients with long-term survival and 216 patients with short-term survival were included. Long-term survivors received immunotherapy (65%), including anti-PD-1 in 86% and combination of an anti-PD-1 and anti-CTLA-4 in 14%; and TT (35%). The Objective Response Rate (ORR) was 76% for anti-PD-1, 80% for combination immunotherapy and 83% for TT. Short-term survivors received immunotherapy (58%), including anti-PD-1 (70%), anti-CTLA-4 (1%), and anti-PD-1 plus anti-CTLA-4 (29%); TT (36%); and chemotherapy (2%). ORR was 7% for anti-PD-1, 0% for anti-CTLA-4, 14% for combination immunotherapy, 53% for TT and 0% for chemotherapy.ConclusionsResponse to first or second-line systemic treatment may be a surrogate for long-term survival patients with advanced melanoma.Clinical trial identificationClinicaltrials.gov: NCT03605771

Filiaciones:
Espinosa, E:
 Univ Autonoma Madrid, Hosp Univ La Paz, Sch Med, CIBERONC, Madrid, Spain

Berciano-Guerrero, MA:
 Hosp Reg Univ HRU, Med Oncol Dept, Inst Invest Biomed Malaga IBIMA, Malaga, Spain

Muñoz-Couselo, E:
 Hosp Univ Vall Hebron, Med Oncol Dept, Barcelona, Spain

 Vall Hebron Inst Oncol VHIO, Barcelona, Spain

Puértolas, T:
 Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain

:
 H Germans Trias i Pujol, ICO Badalona, Inst Catalan Oncol, Med Oncol Dept, Badalona, Spain

Soria, A:
 Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain

Crespo, G:
 Hosp Univ Burgos, Med Oncol Dept, Burgos, Spain

Sanz, LG:
 Hosp Univ Puerta Hierro, Med Oncol Dept, Madrid, Spain

Cerezuela-Fuentes, P:
 Hosp Clin Univ Virgen Arrixaca, Inst Murciano Invest IMIB Arrixaca, Dept Cardiol, Murcia, Spain

de la Rosa, CA:
 Hosp Univ Clin San Carlos, Med Oncol Dept, Madrid, Spain

Majem, M:
 Hosp Santa Creu i St Pau, Med Oncol Dept, Barcelona, Spain

Castaño, AG:
 Hosp Univ Marques Valdecilla, Med Oncol Dept, Santander, Spain

Berrocal, A:
 Hosp Gen Univ Valencia, Med Oncol Dept, Valencia, Spain

Arroyo, FRG:
 Complejo Hosp Univ Pontevedra, Med Oncol Dept, Pontevedra, Spain

de la Borbolla, MR:
 Hosp Univ Valme, Med Oncol Dept, Seville, Spain

Bellido, L:
 Hosp Univ Salamanca, Med Oncol Dept, SAL, Inst Invest Biomed Salamanca IB, Salamanca, Spain

Martínez, JM:
 Hosp Univ Toledo, Med Oncol Dept, Toledo, Spain

Fernández, LA:
 Hosp Universitari Parc Tauli Sabadell, Med Oncol Dept, Sabadell, Spain

Carnicero, AM:
 Hosp San Pedro La Rioja, Med Oncol Dept, Logrono, Spain

Castro, RL:
 Hosp Clin Univ Valladolid, Med Oncol Dept, Valladolid, Spain

Rodríguez, AB:
 Hosp Son Llatzer, Med Oncol Dept, Palma De Mallorca, Spain

Guzmán, JCV:
 Hosp Gen Ciudad Real, Dept Nucl Med, Ciudad Real, Spain

Balea, BC:
 Hosp Lucus Augusti, Serv Med Nucl, Lugo, Spain

Rodríguez, JF:
 Hosp Univ Rio Hortega, Med Oncol Dept, Valladolid, Spain

Bautista, JV:
 Hosp Univ Virgen de las Nieves, Med Oncol Dept, Granada, Spain

Pérez, VN:
 Hosp Univ Costa Sol, Med Oncol Dept, Marbella, Spain

Mujika, K:
 Med Oncol Dept, Onkologikoa Fundazioa, Donosti, Spain

Subias, MC:
 Hosp Clin Univ Lozano Blesa, Med Oncol Dept, Zaragoza, Spain

Algarra, SM:
 Clin Univ Navarra, Med Oncol Dept, Pamplona, Spain

Márquez-Rodas, I:
 Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain

Hosp Univ San Pedro Alcantara, Med Oncol Dept, Caceres, Spain
Hosp Univ Navarra, Med Oncol Dept, Pamplona, Navarra, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
Springer-Verlag Italia, GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 28 Número: 5
Páginas: 1807-1814
WOS Id: 001626269000001
ID de PubMed: 41313559
imagen Green Submitted, hybrid

MÉTRICAS